Kinnate Biopharma Inc.

Kinnate Biopharma Inc. (NASDAQ: KNTE) is a clinical-stage precision oncology company. It is focused on the discovery, design, and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its lead product candidate is exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma, and other solid tumours.

Recent Financial and Business Updates:

• Pipeline Updates:
  • The Investigational New Drug (IND) application for KIN-7136, a potentially brain-penetrant mitogen-activated protein kinase (MEK) inhibitor, has received clearance from the U.S. Food and Drug Administration (FDA). In the second half of 2023, the company plans to initiate a Phase 1 trial, designated as KN-3603, to assess KIN-7136 in adult participants with advanced solid tumors, particularly non-small cell lung cancer driven by the mitogen-activated protein kinase pathway, including cases with brain metastases. The evaluation of KIN-7136 will encompass both monotherapy and its use in combination with Kinnate's investigational pan-RAF inhibitor, exarafenib.
  • The first presentation detailing the structure and discovery of the FGFR inhibitor, KIN-3248, is scheduled for the 2023 American Chemical Society conference on August 16.
  • A poster was presented at the 2023 American Society of Clinical Oncology Annual Meeting, focusing on the genomic landscape analysis based on circulating tumor DNA for assessing molecular brake and gatekeeper mutations in FGFR2.

• Financial Results:
  • As of June 30, 2023, the company held a total of USD204.3 million in cash, cash equivalents, and investments, anticipated to support ongoing operations until early 2025.
  • Research and development expenses for the second quarter of 2023 amounted to USD26.3 million, a rise from USD19.8 million during the same period in 2022.
  • General and administrative expenses for the second quarter of 2023 were USD7.8 million, slightly up from USD7.6 million in the second quarter of 2022.
  • The net loss for the second quarter of 2023 stood at USD31.9 million, compared to USD27.1 million for the corresponding period in 2022.

Technical Observation (on the daily chart)

The stock hit its highest point in the past 52 weeks, reaching USD 10.56 on November 15, 2022, with price correcting by around 88.22%. The Relative Strength Index (RSI) observed over a 14-day period registers at 29.83, indicating oversold conditions. This suggests the potential for a short-term uptick in momentum or a period of consolidation. Furthermore, the stock's current position is situated below both the 21-day Simple Moving Average (SMA) and the 50-day SMA, potentially acting as dynamic short-term resistance levels. Currently, the stock price appears to be forming a double bottom pattern within the range of USD 1.00 to USD 1.20, with expectations of a notable upward surge once it breaches the USD 1.50 levels on the upside.

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing. 

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

How to Read the Charts?

The yellow colour line reflects the 21-period simple moving average (SMA) while the blue line indicates the 50- period simple moving average (SMA). SMA helps to identify existing price trends. If the prices are trading above the 21-period and 50-period moving average, then it shows prices are currently trading in a bullish trend.

The orange colour line in the chart’s lower segment reflects the Relative Strength Index (14-Period) which indicates price momentum and signals momentum in trend. A reading of 70 or above suggests overbought status while a reading of 30 or below suggests an oversold status.

The red and green colour bars in the chart’s lower segment show the volume of the stock. The volume is the number of shares that changed hands during a given day. Stocks with high volumes are more liquid than stocks with lesser volume as liquidity in stocks helps with easier and faster execution of the order.

The Orange colour lines are the trend lines drawn by connecting two or more price points and used for trend identification purposes. The trend line also acts as a line of support and resistance.

Technical Indicators Defined: -

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock. 

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock. 

Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices. 

The reference date for all price data, currency, technical indicators, support, and resistance levels is October 17, 2023. The reference data in this report has been partly sourced from REFINITIV. 

Abbreviations

CMP: Current Market Price

SMA: Simple Moving Average

RSI: Relative Strength Index

USD: United States dollar 

Note: Trading decisions require a thorough analysis by individual. Technical reports in general chart out metrics that may be assessed by individuals before any stock evaluation. The above are illustrative analytical factors used for evaluating the stocks; other parameters can be looked at along with additional risks per se. Past performance is neither an indicator nor a guarantee of future performance.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services. Please note past performance is neither an indicator nor a guarantee of future performance.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this Report.